Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Enhancing Periodontal Regenerative Outcomes With Simultaneous Orthodontic Tooth Movement.

Haggard CA, Pumphrey BJ, Richman CS, Peacock ME, Stern JK.

Compend Contin Educ Dent. 2019 Jan;40(1):36-44.

PMID:
30601020
2.

Pre-orthodontic periodontal augmentation for lower incisor advancement in adolescent patients.

Gray JB, Richman C.

J Clin Orthod. 2018 Oct;52(10):513-527. No abstract available.

PMID:
30346931
3.

C. elegans MANF Homolog Is Necessary for the Protection of Dopaminergic Neurons and ER Unfolded Protein Response.

Richman C, Rashid S, Prashar S, Mishra R, Selvaganapathy PR, Gupta BP.

Front Neurosci. 2018 Aug 10;12:544. doi: 10.3389/fnins.2018.00544. eCollection 2018.

4.

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.

Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M.

Br J Haematol. 2018 Sep;182(6):916-920. doi: 10.1111/bjh.14879. Epub 2017 Aug 2. No abstract available.

PMID:
28771676
5.

Dental Space Deficiency Syndrome: An Anthropological Perspective.

Richman CS.

Compend Contin Educ Dent. 2017 Mar;38(3):180-186.

PMID:
28257225
6.

Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.

Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, Bodhi P, Davis J, Davies SM, Deconinck E, Deeg HJ, Duerst RE, Fasth A, Ghavamzadeh A, Giri N, Goldman FD, Kolb EA, Krance R, Kurtzberg J, Leung WH, Srivastava A, Or R, Richman CM, Rosenberg PS, Toledo Codina JS, Shenoy S, Socié G, Tolar J, Williams KM, Eapen M, Savage SA.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1238-43. doi: 10.1016/j.bbmt.2013.05.021. Epub 2013 Jun 8.

7.
8.
9.

Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.

Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1192-8. Epub 2006 Sep 11.

PMID:
16965873
10.

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.

DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP, O'Donnell RT, DeNardo GL.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7187s-7194s.

11.

Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?

Miers L, Lamborn K, Yuan A, Richman C, Natarajan A, DeNardo S, DeNardo G.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7158s-7163s.

12.

High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.

Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL.

Clin Cancer Res. 2005 Aug 15;11(16):5920-7.

13.

Inactivation of FGF8 in early mesoderm reveals an essential role in kidney development.

Perantoni AO, Timofeeva O, Naillat F, Richman C, Pajni-Underwood S, Wilson C, Vainio S, Dove LF, Lewandoski M.

Development. 2005 Sep;132(17):3859-71. Epub 2005 Jul 27.

14.

Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.

Shen S, DeNardo SJ, Richman CM, Yuan A, Siantar CH, O'Donnell RT, Kroger LA, DeNardo GL.

J Nucl Med. 2005 Jun;46(6):1034-41.

15.

An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.

Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN Jr.

Cancer J. 2004 Sep-Oct;10(5):294-300.

PMID:
15530258
16.

Acute myocardial infarction in hemoglobin SC disease.

Wang H, Laslett LJ, Richman CM, Wun T.

Ann Hematol. 2004 Oct;83(10):622-4. Epub 2004 Aug 5.

PMID:
15300406
17.

Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature.

Rodler E, Welborn J, Hatcher S, Unger K, Larkin E, Gumerlock PH, Wun T, Richman C.

Am J Hematol. 2004 Apr;75(4):231-8. Review.

18.

Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.

DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3938S-44S.

19.

Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.

DeNardo G, Yuan A, Goldstein D, Richman C, O'Donnell R, Shen S, Hartmann Siantar C, DeNardo S.

Cancer Biother Radiopharm. 2003 Apr;18(2):231-7.

PMID:
12804049
20.

Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms.

Mohan S, Richman C, Guo R, Amaar Y, Donahue LR, Wergedal J, Baylink DJ.

Endocrinology. 2003 Mar;144(3):929-36.

21.

Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation.

Hutchinson K, Kopko PM, Muto KN, Tuscano J, O'Donnell RT, Holland PV, Richman C, Paglieroni TG, Wun T.

Transfusion. 2002 Dec;42(12):1567-72.

PMID:
12473136
23.

Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial.

Wang SE, Lara PN Jr, Lee-Ow A, Reed J, Wang LR, Palmer P, Tuscano JM, Richman CM, Beckett L, Wun T.

Am J Hematol. 2002 Jul;70(3):191-4.

24.

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

O'Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN, Griffith IJ, Goldstein DS, Kukis DL, Martinez GS, Mirick GR, DeNardo GL, Meyers FJ.

Clin Cancer Res. 2001 Jun;7(6):1561-8.

25.
26.

Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies.

Richman CM, DeNardo SJ.

Crit Rev Oncol Hematol. 2001 Apr;38(1):25-35. Review.

PMID:
11255079
27.

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

Lara PN Jr, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS.

J Clin Oncol. 2001 Mar 15;19(6):1728-33.

PMID:
11251003
28.

Postnatal and pubertal skeletal changes contribute predominantly to the differences in peak bone density between C3H/HeJ and C57BL/6J mice.

Richman C, Kutilek S, Miyakoshi N, Srivastava AK, Beamer WG, Donahue LR, Rosen CJ, Wergedal JE, Baylink DJ, Mohan S.

J Bone Miner Res. 2001 Feb;16(2):386-97.

29.

Evidence that IGF-binding protein-5 functions as a growth factor.

Miyakoshi N, Richman C, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S.

J Clin Invest. 2001 Jan;107(1):73-81.

30.

Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice.

Miyakoshi N, Richman C, Qin X, Baylink DJ, Mohan S.

Endocrinology. 1999 Dec;140(12):5719-28.

PMID:
10579337
31.

Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.

Richman CM, DeNardo SJ, O'Donnell RT, Goldstein DS, Shen S, Kukis DL, Kroger LA, Yuan A, Boniface GR, Griffith IJ, DeNardo GL.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3243s-3248s.

PMID:
10541370
32.

Strategies for developing effective radioimmunotherapy for solid tumors.

DeNardo GL, O'Donnell RT, Kroger LA, Richman CM, Goldstein DS, Shen S, DeNardo SJ.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3219s-3223s. Review.

PMID:
10541367
33.

Recombinant human insulin-like growth factor-binding protein-5 stimulates bone formation parameters in vitro and in vivo.

Richman C, Baylink DJ, Lang K, Dony C, Mohan S.

Endocrinology. 1999 Oct;140(10):4699-705.

PMID:
10499528
34.

Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.

Denardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, Kroger LA, Perez EA, Denardo GL.

Anticancer Res. 1998 Nov-Dec;18(6A):4011-8.

PMID:
9891439
35.

Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.

DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako Q, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, DeNardo SJ.

Clin Cancer Res. 1998 Oct;4(10):2483-90.

36.

Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma.

Richman CM, Schuermann TC, Wun T, Malik R, O'Donnell RT, DeNardo GL, DeNardo SJ.

Cancer. 1997 Dec 15;80(12 Suppl):2728-32.

PMID:
9406731
37.

Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.

DeNardo SJ, Kroger LA, Lamborn KR, Miers LA, O'Donnell RT, Kukis DL, Richman CM, DeNardo GL.

Cancer. 1997 Dec 15;80(12 Suppl):2583-90.

PMID:
9406713
38.

Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.

DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL.

J Nucl Med. 1997 Aug;38(8):1180-5.

39.

Person perception as a function of marital status and age.

Stacy NL, Richman CL.

J Soc Psychol. 1997 Jun;137(3):395-7. No abstract available.

PMID:
9200975
40.

Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.

Denardo SJ, O'Grady LF, Richman CM, Goldstein DS, O'Donnell RT, Denardo DA, Kroger LA, Lamborn KR, Hellström KE, Hellström I, Denardo GL.

Anticancer Res. 1997 May-Jun;17(3B):1745-51.

PMID:
9179228
41.

Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.

Denardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, Meares CF, Yuan A, Welborn JL, Denardo GL.

Anticancer Res. 1997 May-Jun;17(3B):1735-44.

PMID:
9179227
42.
43.

Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.

Ghalie R, Richman CM, Adler SS, Cobleigh MA, Korenblit AD, Manson SD, McLeod BC, Taylor SG 4th, Valentino LA, Wolter J, et al.

J Clin Oncol. 1994 Feb;12(2):342-6.

PMID:
8113841
44.

Sequential transplants using mobilized peripheral blood progenitor cells.

Ghalie R, Richman CM, Bender JG, McLeod BC, Lee W, Czyzewski A, Manson S, Cobleigh MA, Reed S, Pierre R, et al.

J Clin Apher. 1994;9(3):176-82.

PMID:
7535760
45.

Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6.

DeNardo SJ, O'Grady LF, Richman CM, DeNardo GL.

Adv Exp Med Biol. 1994;353:203-11.

PMID:
7527179
46.

Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation.

Ghalie R, Porter C, Radwanska E, Fitzsimmons W, Richman C, Kaizer H.

Am J Hematol. 1993 Apr;42(4):350-3.

PMID:
8493984
47.

Enhancement of clinical radioimmunotherapy for cancer and the role of cytokines.

DeNardo SJ, DeNardo GL, Richman CM.

J Natl Cancer Inst. 1992 Mar 18;84(6):374-5. No abstract available.

PMID:
1538409
48.

Generic versus brand name drug prescribing by resident physicians in Pennsylvania.

Shulkin DJ, Giardino AP, Freenock TF Jr, Henriksen DS, Richman C, Friedlander MS, Pandelidis SM, Heywood TJ.

Am J Hosp Pharm. 1992 Mar;49(3):625-6. No abstract available.

PMID:
1598941
49.

Peripheral blood stem cell transplantation: impact on procedure load and workload in an apheresis unit.

Ghalie R, McLeod B, Richman C, Valentino L, Manson S, Netols C, Kaizer H.

J Clin Apher. 1992;7(4):201-7.

PMID:
1363730
50.

Involved field radiation, fractionated total body irradiation, high dose cyclophosphamide, and autologous bone marrow transplantation in the treatment of malignant lymphomas.

Ghalie R, Richman CM, Adler SS, Korenblit AD, Kramer TS, Manson S, Dolce A, Kaizer H.

Bone Marrow Transplant. 1991 Jul;8(1):41-5.

PMID:
1912954

Supplemental Content

Loading ...
Support Center